< Previous70FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0427Antimicrobials use estimation in 2020 from the SARIMA model in Japan A. Ono* (Tokyo, Japan), R. Koizumi, S. Tsuzuki, Y. Asai, M. Ishikane, Y. Kusama, N. Ohmagari O0428Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients S. Tsuzuki* (Antwerp, Belgium), Y. Miyazato, M. Terada, S. Morioka, N. Ohmagari, B. Philippe OS104 13:30 - 14:30 Hall D 1-Hour Case Session Challenging mycobacterial infections ChairDelane Shingadia (London, United Kingdom) O0429Tuberculosis meningitis: a 30-year review F. Sánchez-Martínez* (Barcelona, Spain), M.D.M. Arenas-Miras, S. Castañeda-Espinosa, N. Jové-Caballé, E. Carrió-Díez, H. Knobel, J.P. Horcajada O0430Mycobacterium haemophilum in Singapore: a multi-centre descriptive case series J. Sim* (Singapore, Singapore), C.M.D. Lai, E.P. Conceicao, J.X.J. Soh, T.T. Tan, C.C. Ang, C.F. Yung, S.T. Thio, B.K.W. Yeo, J.Y. Pan, S.X. Lee, S.Y. Tan, S. Sadarangani, L.H. Sng O0431Nosocomial transmission of Mycobacterium abscessus in patients with COVID-19 admitted to an intensive care unit in Madrid A. Estévez* (Madrid, Spain), V. Sampériz, M.J. Ruiz Serrano, M. Marín, M. Sancho, B. Moreno, A. Garrido, C. Mata, L. Perez-Lago, D. García De Viedma, B. Padilla, P. Muñoz O0432Cutaneous tuberculosis verrucosa cutis presenting as a fungating mass on the foot: a case report A. Uy* (Quezon City, Philippines), A. Masbang O0433Clinical description, antimicrobial resistance, and treatment outcomes for patients with invasive Mycobacterium chelonae infection from one UK hospital: a 15-year retrospective case series J. Meiring* (Sheffield, United Kingdom), A. Temple, S. Francis, H. Kaur, J. Snowden, D. Partridge OF105 13:30 - 14:30 Hall H 1-Hour Mini-oral Flash Session Epidemiology of parasites, here and there ChairsAnna Checkley (London, United Kingdom) Florence Robert-Gangneux (Rennes, France) O0433AParasites (Blastocystis hominis, Dientamoeba fragilis, Cryptosporidiumspp., Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia) laboratory diagnostic in Latvia 2019-2021 K. Ventins* (Riga, Latvia), O. Savicka, T. Bogurdovica, S. Nikisins O0433BA machine learning model for evaluating strongyloidiasis screening strategies in immigrant populations A. Rodríguez-Guardado* (Oviedo, Spain), A. García- Pérez, J. Fernández-Martínez, J. Boga, E. De Andrés, L. Casado, J. Fernández, F. Vázquez, M. Rodríguez-Pérez O0433CMonitoring soil-transmitted helminth infections in treated and non-treated individuals over three years of community-wide mass drug administration within the Geshiyaro project in Ethiopia S. Santiago* (London, United Kingdom), R. Maddren, L. Toby, K. Suprabhath, F. Ewnetu, C. Melkie, M. Hussein, W. Yonas, T. James, P. Anna, O. Alison, F. Kathryn, A. Ufaysa, M. Birhan, M. Zelalem, T. Geremew, S. Mihretab, R. Roy O0434Occurrence ofGiardia duodenalis and Cryptosporidiumspecies, not-related to travel, in a country generally with a high hygienic standard G.N. Hartmeyer* (Odense, Denmark) O0435Higher than expected incidence of leishmaniasis in the city of Madrid (Spain): possible relationship to a close outbreak focus J. Alonso-Carrillo* (Madrid, Spain), S. Castaño, M. Prieto, N. Valdeolivas, A. López-Alba, M. Fernández-Ruiz, R. San Juan, M. Lizasoain, A. Pérez De Ayala, J.M. Aguado, F. López-Medrano O0436The first detection of Leishmania infantum parasite in Forcipomyia species L. Remadi* (Monastir, Tunisia), H. Baba, D. Slama, D. Farjallah, H. Babba, N. Haouas O0437Genomic epidemiology ofCryptosporidium parvumin Europe G. Bellinzona* (Pavia, Italy), T. Nardi, M. Castelli, T. Autio, Y. Blanchard, R.M. Chalmers, R. Davidson, A. De Jong, T. Embom, J. Gomes, G. Karadjian, C. Klotz, P. Jokelainen, E. Östlund, J. Plutzer, L.J. Robertson, G. Robinson, A.R. Sannella, J. Sroka, C. Rune Stensvold, K. Troell, P. Vatta, D. Sassera, S.M. Cacciò O0438Endemic lizards Gallotia gallotiinfected by invasive nematode Angiostrongylus cantonensis in Tenerife, Spain E. Izquierdo-Rodriguez* (La Laguna, Spain), L. Anettová, P. Foronda, D. Modrý O0439Pilot survey of cystic echinococcosis in Masaai livestock-keeping communities of northern Tanzania F. Tamarozzi* (Negrar Di Valpolicella, Italy), T. Kibona, W. De Glanville, T. Mappi, E. Adonikamu, A. Salewi, K. Misso, V. Maro, A. Casulli, A. Santoro, F. Santolamazza, B. Mmbaga, C. Sarah Sunday, 24 April 2022Scientific Programme 71FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 OF106 13:30 - 14:30 Hall K 1-Hour Mini-oral Flash Session All about intracellular and rare bacteria ChairsMatilda Berkell (Antwerpen, Belgium) Gilbert Greub (Mollie-Margot, Switzerland) O0440“When old drugs learn new tricks”: drug repurposing of thioridazine to treat Salmonella infections D. Alves Ferreira* (Dublin, Ireland), C. Roma Rodrigues, P.V. Baptista, A. Fernandes, M. Martins O0441Identification of Streptomyces spp. in a clinical sample: always a contamination? Results of a French national retrospective study E. Gras* (Paris, France), E. Bergeron, M. Puges, M. Ducours, C. Leleux, L. Amoureux, B. Jean, I. Bendjelloul, F. Camelena, R. Chenouard, R. Mahieu, A. Toro, A. Lecoustumier, O. Lortholary, O. Lemenand, V. Rodriguez-Nava, D. Lebeaux O0442The retropepsin-type protease APRc as a novel Ig-binding protein and moonlighting immune evasion factor of Rickettsia I. Simões* (Coimbra, Portugal), P. Curto, A. Barro, C. Almeida, R.S. Vieira-Pires O0443Characterisation of truncated internalin A in Listeria monocytogenes clinical isolates within the surveillance of invasive listeriosis in Lombardy region, northern Italy M. Gori* (Milan, Italy), C. Fappani, S. Piazza, G. Magagna, E. Spinelli, S. Bianchi, D. Colzani, G. Finazzi, A. Amendola, E. Tanzi O0444Fluorescence in situ hybridisation for detecting Coxiella burnetii in tissue samples: not as golden as we hoped J.M. Weehuizen* (Utrecht, Netherlands), S.B. Buijs, T.K. Jensen, A.I.M. Hoepelman, C.P. Bleeker-Rovers, P.C. Wever O0445Next-generation sequencing of historic and contemporary strains of Fusobacterium necrophorum at the UK anaerobe reference unit: what does it reveal? M. Perry* (Cardiff, United Kingdom), K. Vranckx, T. Morris O0446Burden of Lyme disease (BOLD) study: a prospective active surveillance study in European endemic regions, interim results A. Loew-Baselli* (Vienna, Austria), A. Pilz, J. Stark, L.R. Harper, J.S. Berglund, V. Cibik, J. Weimer, A. Moniuszko-Malinowska, L. Dybova, D. Zakova, B. Parslow, J. Edwards, K. Chauhan, S. Valluri, L. Jodar, B. Gessner, B. Elizabeth O0447Implementation of Campylobacter laboratory surveillance using whole genome sequencing in the Netherlands M. Van Den Beld* (Bilthoven, Netherlands), R. Pijnacker, O.E. Van Den Berg, K. Van Der Zwaluw, A. Hernandez Segura, E. Franz, T. Bosch O0448Invasive Aggregatibacter species infections in a London teaching hospital over a 4-year period: a case series of 27 patients A. Bapat* (London, United Kingdom), O. Lucey, M. Eckersley, S. Ranasinghe, J. Lambourne KN10714:45 - 15:45Hall A Keynote lecture AI revolution in medicine Chairs Adrian Egli (Basel, Switzerland) Vitali Sintchenko (Sydney, Australia) K044914:45 Suchi Saria (Baltimore, United States) Suchi Saria, PhD, is the Founder and CEO of Bayesian Health, the John C. Malone endowed chair and Associate Professor of Computer Science, Statistics and Health Policy, and the Director of the Machine Learning, AI and Healthcare Lab at Johns Hopkins University. Her research has pioneered the development of next generation diagnostic and treatment planning tools that use statistical machine learning methods to individualize care. She has written several of the seminal papersinthefieldofMLanditsuseforimprovingpatient care and has given over 250 invited keynotes and talks to organizations including the NAM, NAS, and NIH. Dr. Saria has served as an advisor to several Fortune 500 companies and her work has been funded by leading organizations including the NIH, FDA, NSF, DARPA and CDC. At Bayesian Health, Dr. Saria is operationalizing her decades ofresearchinthefieldtomakehealthcareproactiveby empowering physicians, nurses, and care team members with real-time data to save lives. Dr. Saria has been featured in Bloomberg News and PBS NOVA and she has won several awards for excellence in AI and care delivery, including IEEE’s “AI’s 10 to Watch”, Sloan Fellow, MIT Tech Review’s “35 Under 35”, National Academy of Medicine’s list of “Emerging Leaders in Health and Medicine”, DARPA’s List of Rising Stars, World Economic Forum’s 100 Brilliant Minds Under 40, Rock Health’s “Top 50 in Digital Health”, The Armstrong Award for Excellence inQualityandSafety;Node.Health’sBestinClassDigitalHealth InterventionAward;andSocietyofCriticalCareMedicine’s AnnualScientificAward. Fireplace Session24 April, 16:00 - 17:00 PH SY108 14:45 - 15:45 Hall H Symposium Imported cutaneous leishmaniasis in Europe by the thousand: is it all the same? ChairsSara Karlsson Sobirk (Lund, Sweden) Kristine Morch (Bergen, Norway) S045014:45Imported cutaneous leishmaniasis in migrants Özgür Kurt (Istanbul, Turkey) S045115:15Cutaneous leishmaniasis in South America Dalila Martinez (Lima, Peru) Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)72FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 ID SY109 14:45 - 15:45 Hall J Symposium The changing picture of childhood pneumonia ChairsDavid Goldblatt (London, United Kingdom) Catherine Satzke (Melbourne, Australia) S045214:45Impact of COVID-19 pandemic on epidemiology of childhood pneumonia Shabir Madhi (Randburg, South Africa) S045315:15Impact of the pandemic on childhood vaccination globally Kate O’Brien (Geneva, Switzerland) OS110 14:45 - 15:45 Hall I 1-Hour Oral Session Elimination of HBV and HCV ChairsArjan Harxhi (Tirana, Albania) Dorota Zar ę bska-Michaluk (Kielce, Poland) O0454Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: a large prospective cohort study L. Yi* (Beijing, China), X. Yingchun O0455ScanVir: a new concept towards the end of hepatitis C in 2025 in France M.L. Debette-Gratien* (Limoges, France), S. Alain, S. François, C. Rigaud, P. Carrier, C. Chevalier, B. Abraham, A.L. Burgevin, B. Denenes, L. Courat, J. Zattoni-Leroy, E. Caux-Nussbaum, P. Nubukpo, V. Loustaud-Ratti O0456Impact of the COVID-19 pandemic on treatment access and follow-up of viral hepatitis patients N. Baykam* (Çorum, Turkey), F. Eser, R. Güner, Y. Gürbüz, M. Akdo ğ an, Z. Bilgiç, N. Korkmaz, D. Arı, G. Ş anlıda ğ , Ş . Kesim Uçar, T. Düzenli, T. Yamazhan O0457HCV micro-elimination in the hospital setting: the results of the HCV-free Caserta hospital project M. Pisaturo* (Naples, Italy), V. Messina, L. Alessio, A. Russo, N. Coppola O0458Impact of the COVID-19 epidemic on reported chronic hepatitis C in the Netherlands, 2019- 2021 E. Den Boogert* (Bilthoven, Netherlands), P. Zantkuijl, I.K. Veldhuijzen, E. Op De Coul OS111 14:45 - 15:45 Hall D 1-Hour Case Session Management of orthopaedic infections ChairMarjan Wouthuyzen-Bakker (Groningen, Netherlands) O0459Bacteriophage therapy: clinical experience in the management of eight patients withdifficult-to- treat infections P. Morovic* (Berlin, Germany), L. Ponce Benavente, T. Tkilaishvili, D. Margaryan, S. Karbysheva, P. Carsten, A. Trampuz O0460Tropheryma whipplei spondylodiscitis: case report A. Ferrari* (Padua, Italy), S. Lo Menzo, S. Gardin, F. Raumer, M. Trevenzoli, A. Cattelan O0461First Italian case of successful personalised phage therapy in addition to antibiotic in the treatment of chronic hip prosthesis infection caused by Pseudomonas aeruginosa N. Cesta* (Rome, Italy), M. Pini, T. Mulas, E. Ippolito, J. Wagemans, L. Sarmati, R. Lavigne, A. Tavanti, M. Andreoni, M. Di Luca O0462Persistent Brucella Melitensisbacteraemia due to bilateral prosthetic knee infection: a case report C. Aldieri* (Cuneo, Italy), E. Borgogno, E. Monge, F. Sordella, R. Curetti, V. Del Bono O0463A rare case of periprosthetic streptobacillosis: rapid identification via nanopore sequencing after inconclusive VITEK MS results R. Spott* (Jena, Germany), B. Schleenvoigt, B. Edel, M.W. Pletz, C. Brandt OF112 14:45 - 15:45 Hall K 1-Hour Mini-oral Flash Session Update on epidemiology and resistance in Staphylococcus aureus and Enterococcus ChairsSören G. Gatermann (Bochum, Germany) Margreet C. Vos (Rotterdam, Netherlands) O0464Antimicrobial resistance and genetic diversity of Enterococcus and Staphylococcus isolates from wastewater and environmental water samples from two South African provinces J. Makumbi* (Pretoria, South Africa), M. Kock, S. Ogundare, A. Smith, G. Van Der Zel, M. Ehlers O0465Staphylococcus aureus carriage variation in the nasotracheal cavities of storks from southern Spain, with a focus on the MSSA-CC398 clone I.N. Abdullahi* (Logroño, Spain), G. Juárez- Fernández, D. Mínguez-Romero, P. Eguizábal, R. Fernández-Fernández, U. Hoffle, M. Zarazaga, C. Lozano, C. Torres O0466Emergence of staphylococcal non-wild-type populations to biocides in a One Health perspective: are there reasons for concern? S.S. Costa* (Lisbon, Portugal), C. Ferreira, C. Morais, P. Abrantes, C. Pomba, I. Couto O0467Vancomycin-resistant Enterococcus faecium causing hospital infections in Porto, Portugal (2009-2020): a retrospective analysis A.C. Almeida-Santos* (Porto, Portugal), B. Duarte, A.P. Pereira, M. Cabral, L.M. Silva, H. Ramos, A. Read, V. Alves, C. Novais, A.R. Freitas, L. Peixe O0468Prevalence of pvl-positive methicillin-resistant Staphylococcus aureus (MRSA) isolated from imported, farmed fish at retail in Germany S. Maurischat* (Berlin, Germany), S. Schaarschmidt, T. Lienen, M. Grobbel, B.A. Tenhagen, K. AltScientific Programme 73FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 O0469Transmission of methicillin-susceptible Staphylococcus aureus among healthcare workers, patients and the environment in a large acute hospital with a history of endemic methicillin-resistant Staphylococcus aureus (MRSA) under non-outbreak conditions investigated using whole genome sequencing P. Kinnevey* (Dublin, Ireland), A. Kearney, M. Earls, T. Poovelikunnel, G. Brennan, A. Shore, H. Humphreys, D. Coleman O0470Fine-typing of the endemic vancomycin- resistant Enterococcus faecium ST117 clone from Germany K. Xanthopoulou* (Cologne, Germany), F. Dyrkell, D. Arnellos, F.B.A.G. Erre, H. Seifert, P.G. Higgins O0471Genomic epidemiology and characterisation of penicillin-sensitive MSSA isolates from invasive bloodstream infections in China: an increasing prevalence and higher diversity in genetic typing be revealed W. Zhou* (Hangzhou, China), Y. Jin, Y. Xiao O0472Linezolid-resistant VRE (Enterococcus faecium) from hospital patients in Germany, 2016-2020 G. Werner* (Wernigerode, Germany), C. Fleige, R. Weber, M. Fischer, J. Bender VW113 14:45 - 15:45 Arena 2 Virtual Walk Through Efficacy and immunity of established vaccines ModeratorJoanna Maria Zajkowska (Bialystok, Poland) ReviewerMichael Dalager-Pedersen (Aalborg, Denmark) SY114 16:15 - 18:15 Hall A Symposium Late-breaking research from The Lancet group ChairsEmma Grainger (London, United Kingdom) Zoe Mullan (London, United Kingdom) Details on the selected publications will be availble at a later stage ID SY115 16:15 - 18:15 Hall B Symposium Updates on HIV treatment and prevention ChairsJose Arribas (Madrid, Spain) Georg Behrens (Hannover, Germany) S047316:15Progress toward reaching HIV prevention and treatment targets in Europe Teymur Noori (Solna, Sweden) S047416:45HIV treatment: which are the drugs? Marta Vasylyev (Lviv, Ukraine) S047517:15HIV and the cure: what is new in the HIV the vaccine research? Simona Ruta (Bucharest, Romania) S047617:45Patients perspectives on PrEP Tamás Bereczky (Berlin, Germany) Co-organised with: European AIDS Clinical Society (EACS) CM SY116 16:15 - 18:15 Hall E Symposium Host and viral factors in COVID-19, what makes us sick? ChairsMario Ramirez (Lisbon, Portugal) Annelies Verbon (Utrecht, Netherlands) S047716:15Host factors for disease severity of COVID-19 Qian Zhang (New York, United States) S047816:45The interplay between host and viral factors in the evolving COVID-19 pandemic Marion Koopmans (Rotterdam, Netherlands) S047917:15Studying T-cell response after vaccination in COVID-19 transplant recipients Coretta Van Leer Buter (Groningen, Netherlands) S048017:45Genetic variants in the human population driving severe COVID Alessandra Renieri (Siena, Italy) Co-organised with: UEMS Section of Medical Microbiology, UEMS Section of Infectious Diseases, ESCMID Study Group for Infections in the Elderly (ESGIE) ID SY117 16:15 - 18:15 Hall F Symposium Emerging priorities and developments for antifungals and fungal infections ChairsAna Alastruey-Izquierdo (Madrid, Spain) Arnaldo Colombo (São Paulo, Brazil) S048116:15Where do novel antifungals fit in clinical practice? Nina Khanna (Basel, Switzerland) S048216:45New fungal diagnostic tests to support the use of novel antifungal agents Luis Ostrosky-Zeichner (Houston, United States) S048317:15WHO Fungal Priority Pathogens List for research and development Hatim Sati (Geneva, Switzerland) S048417:45Challenges in clinical management of invasive fungal infections in low- and middle-income countries Arunaloke Chakrabarti (Chandigarh, India) Co-organised with: International Immunocompromised Host Society (ICHS), World Health Organization (WHO)74FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 ID EW118 16:15 - 18:15 Hall I Educational Workshop The different faces of Lyme borreliosis ChairsAnna J. Henningsson (Jönköping, Sweden) Mateusz Markowicz (Vienna, Austria) W048516:15In the skin: dermatologic manifestations of Lyme borreliosis Franc Strle (Ljubljana, Slovenia) W048616:45In the brain: Lyme neuroborreliosis Randi Eikeland (Kristiansand, Norway) W048717:45In the joints: Lyme arthritis Benoît Jaulhac (Strasbourg, France) Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR) ID EW119 16:15 - 18:15 Hall J Educational Workshop How to make clinical trials more efficient ChairsMarc J.M. Bonten (Utrecht, Netherlands) Herman Goossens (Edegem, Belgium) W048816:15Which operational factors determine the efficiency of clinical trial execution Marouan Zarrouk (Wuppertal, Germany) W048916:45Which design aspects can enhance clinical trial efficiency Marlieke E.A. De Kraker (Geneva, Switzerland) W049017:45What is an adaptive platform trial Cornelis H. Van Werkhoven (Utrecht, Netherlands) Co-organised with: European Clinical Research Alliance on Infectious Diseases (ECRAID) OS120 16:15 - 18:15 Hall C 2-Hour Oral Session Sepsis biomarkers: from gene to score ChairsPierre-Yves Bochud (Lausanne, Switzerland) Fanny Lanternier (Paris, France) O0491Is invasive pneumococcal disease a marker of an underlying primary immunodeficiency? A. Gwee* (Melbourne, Australia), L.K. Phuong, A. Cheung, T. Cole, R. Agrawal, C. Butters, J. Clark, N. Curtis, A. Daley, H. Dobinson, C. Frith, N.S. Hameed, H. Hernstadt, P. Loke, S. Ojaimi, B. Mcmullan, E.G. Sharp, P. Sinnappurajar, T. Templeton, S. Wen O0492Identification of conserved detrimental host immune response predicts severity of bacterial and viral infections P. Khatri* (Palo Alto, United States), M. Freedman, H. Zheng, A. Rao, L. Murphy Jones, D. Dermadi, B. Solomon, L. Kalesinskas O0493Genome wide association study reveals pathogen genomic factors associated with patient outcome in Escherichia coli bloodstream infections S. Lipworth* (Oxford, United Kingdom), K. Vihta, K. Chau, L. Barker, S. George, J. Kavanagh, T. Davies, A. Vaughan, M. Andersson, K. Jeffery, S. Oakley, M. Morgan, S. Hopkins, T. Peto, D. Crook, A.S. Walker, N. Stoesser O0494A robust whole blood mRNA combination identify septic patients at high risk of mortality at day-28 after ICU admission L. Kreitmann* (Lyon, France), M.A. Cazalis, G. Monneret, F. Conti, A. Pachot, K. Brengel-Pesce, J.F. Llitjos O0495A novel 29-mRNA host response test to predict bacterial infections in the emergency department K. Tong-Minh* (Rotterdam, Netherlands), O. Liesenfeld, Y. Van Der Does O0496Developing a sepsis clinical response score to predict mortality in neonates hospitalised in low- and middle-income settings: the NeoSep Recovery Score W. Stöhr* (London, United Kingdom) O0497Early diagnosis of sepsis using novel biomarkers fibroblast growth factor 21 (FGF21) & neutrophil granularity intensity (NEUT-GI) A. Ravindra* (Jodhpur, India), V. Jha, M.K. Garg, D. Kumar, G.K. Bohra, D.S. Meena, N. Midha, S. Khichar, N. Santhanam, A.H. Purohit, P. Purohit, A. Rohila O0498Evaluation of a rapid cellular host response test for risk of development of sepsis in various suspected infection patients in the emergency department (ED) H. O’Neal* (Baton Rouge, United States), R. Sheybani, T. Caffery, H. Tse, A. Shah, C. Thomas O0499BIRC6 modifies risk of invasive bacterial infection in Kenyan children J. Gilchrist* (Oxford, United Kingdom), S. Kariuki, J. Watson, G. Band, S. Uyoga, C. Ndila, N. Mturi, S. Mwarumba, M. Mosobo, S. Mohammed, K. Rockett, A. Mentzer, D. Kwiatkowski, A. Hill, J. Scott, T. Williams O0500A trans-ancestry genomics-based approach to study the interplay between the immune system, pathogen virulence, and HLA type, ancestry and sepsis outcome S. Mangul* (Topanga, United States) Sunday, 24 April 2022Scientific Programme Programme Committee Natacha Couto, Bath, United Kingdom, Lauren Cowley, Bath, United Kingdom, Edward Feil, Bath, United Kingdom, Benjamin Howden, Melbourne, Australia Kristin Hegstad, Tromsø, Norway, Ângela Novais, Porto, Portugal Sandra Reuter, Freiburg, Germany, Samuel Sheppard, Bath, United Kingdom, Guido Werner, Wernigerode, Germany, Contact: conferences@escmid.org Find more information and registration information on our website www.escmid.org/research_projects/escmid_conferences/immem_xiii “Establishing whole genome sequencing at the core of epidemiological surveillance” Platforms for genome-based typing and epidemiology Incorporating new data types for real-time, genome-based surveillance Genome-based nomenclature Zoonosis, intensive food production and One Health Genomic epidemiology of neglected pathogens Genomic sequencing in LMIC The promise of long read sequencing Plasmid biology 2.0 Lessons learned from COVID-19 Metagenomics and Public Health 13th International Meeting on Microbial Epidemiological Markers (IMMEM XIII) Bath, United Kingdom 14–17 September 2022 Register now!76FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 OS121 16:15 - 18:15 Hall G 2-Hour Oral Session Genomic epidemiology of nosocomial infections ChairsPatrick Harris (Herston, Australia) Guido Werner (Wernigerode, Germany) O0501Hypervariable-Locus Melting Typing (HLMT) protocol for the simultaneous detection and typing of Serratiamarcescens: a rapid and cost effective tool to limit outbreaks in neonatal intensive care units (NICUs) F. Comandatore* (Milan, Italy), A. Alvaro, A. Piazza, M. Perini, A.R. Pasala, S. Papaleo, S. Panelli, T. Nardi, S.G. Rimoldi, C. Mauri, M. Corbella, A. Cavallero, C. Farina, G.V. Zuccotti O0502Whole genome sequencing reveals two simultaneous outbreaks involving VIM-2 positive ST111 and blaOXA-74 positive ST235 Pseudomonas aeruginosa A. Rath* (Regensburg, Germany), S. Blaas, M. Pfeifer, B. Kieninger, J. Fritsch, A. Caplunik- Pratsch, W. Schneider-Brachert, T. Holzmann O0503Dissemination of a mosaic transposon carrying 14 different antimicrobial resistance genes driven by a polyclonal outbreak in two hospitals L. Van Alphen* (Maastricht, Netherlands), C. Jamin, E. Heddema, W. Van Der Zwet, C. Hoebe, P. Savelkoul O0504Comprehensive genomic investigation into in- host evolution of vancomycin resistant Enterococcus faecium over 3.5 years H. Seth-Smith* (Basel, Switzerland), A. Durovic, T. Roloff, M. Meola, C. Casanova, S. Tschudin-Sutter, A. Egli O0505Simulation of a real-time transmission surveillance using Fourier-transform infrared spectroscopy and whole genome sequencing for strain typing S. Wolf* (Tübingen, Germany), E. Barth-Jakschic, B. Bader, S. Peter, J. Liese O0506Transmission routes of Pseudomonas aeruginosa in an intensive care unit identified by WGS C. Couchoud* (Besançon, France), X. Bertrand, B. Valot, D. Hocquet O0507Genomic epidemiology and characterisation of methicillin-resistantStaphylococcus aureus from bloodstream infections in China Y. Jin* (Hangzhou, China), W. Zhou, Y. Xiao O0508Vancomycin-resistant Enterococcus faecium isolates attributed to clusters among hospitalised patients across different hospitals and hospital trusts in Berlin, Germany: results from routine outbreak and transmission analyses F. Maechler* (Berlin, Germany), A. Weber, P. Gastmeier, M. Behnke, A. Kola O0509Routes of transmission of VIM-positive Pseudomonas aeruginosain the adult intensive care unit: an analysis of 9 years of surveillance at a university hospital using a mathematical model A. Büchler* (Rotterdam, Netherlands), T.M. Pham, A.F. Voor In ‘h Holt, J.A. Severin, M.C.J. Bootsma, D. Gommers, M.E. Kretzschmar, M.C. Vos O0510Clinical implementation of routine whole genome sequencing for hospital infection control of multidrug-resistant pathogens B. Forde* (Brisbane, Australia), P. Harris, A. Jennison, K. Hajkowicz, G. Playford, J. Clark, S. Beatson, D. Paterson OS122 16:15 - 18:15 Hall H 2-Hour Oral Session AMR Acinetobacter, Pseudomonas and Salmonella: what is new? ChairsAlvaro Pascual Hernandez (Seville, Spain) Fusun Can (Istanbul, Turkey) O0511Origin, phylogeny, and transmission of the epidemic clone ST208 of carbapenem-resistant Acinetobacter baumannii on a global scale Y. Gao* (Beijing, China), H. Li, H. Chen, J. Zhang, R. Wang, Z. Wang, H. Wang O0512Trends of carbapenem-resistantAcinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa in Spain, 2012-21 Á. Asensio Vegas* (Madrid, Spain), M. Cantero Caballero, L.M. Parra Ramírez, A. Vallejo Plaza, R.M. Orti Bordas, I. Salcedo Leal O0513The strategic typhoid alliance across Africa and Asia (STRATAA): genetic epidemiology of typhoidal Salmonella in Blantyre Malawi, Kathmandu Nepal and Dhaka Bangladesh Z. Dyson* (London, United Kingdom), P.M. Ashton, J.E. Meiring, S. Duchene, F. Khanam, A.C. Chirambo, C.L. Msefula, H.C. Banda, B.C. Kutambe, A. Karkey, M. Shakya, S. Tonks, C. Dolecek, S.J. Dunstan, J.D. Clemens, V.E. Pitzer, F. Qadri, B. Basnyat, M.A. Gordon, R.S. Heyderman, G. Dougan, S. Baker, A.J. Pollard, K.E. Holt O0514Antimicrobial resistance and genomic characterisation ofAcinetobacter baumannii andPseudomonas aeruginosaclinical isolates from a nationally representative survey in Saudi Arabia M. Doumith* (Riyadh, Saudi Arabia), R. Bawazeer, S. Alhassinah, A. Alswaji, M. Alzayer, E. Alrashidi, A. Alshahrani, L. Okdah, S. Aljohani, H. Balkhy, M. Alghoribi O0515Molecular characterisation of carbapenem non-susceptible strains of Acinetobacter baumannii and Pseudomonas aeruginosa isolated from a hospital in southern Lima F. Guibert* (Lima, Peru), J. Choque-Matos, K. Espinoza, K. Ocampo, C. Valera, M.J. Pons, J. RuizScientific Programme 77FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 O0516Characterisation of extensively and pan-drug resistant Acinetobacter baumannii clinical isolates obtained from private and public hospitals in South Africa C. Buys* (Pretoria, South Africa), J. Pitout, K.A. Strydom, C. Kingsburgh, B. Skosana, M. Kock O0517Characterisation of Acinetobacter baumannii- calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK phase III trial A. Miller* (Waltham, United States), S. Mcleod, D. Chabas, G. Poirier, D. Altarac O0518Carbapenemase producing Salmonella from non- human sources in Germany: an update J. Fischer* (Berlin, Germany), A. Bloch, E. Junker, G. Raatz, M. Grobbel, A. Irrgang, C. Deneke, I. Szabo O0519Large-scale analysis of carbapenem-resistant Acinetobacter baumannii reveals patterns of dissemination of ST clades associated with antibiotic resistance M.N. Lurie-Weinberger* (Tel Aviv, Israel), S. Frenk, E. Temkin, A. Keren-Paz, R. Rov, N. Rakovitsky, L. Wullfhart, A. Nutman, M. Paul, G.L. Daikos, E. Durante-Mangoni, D. Yahav, A. Skiada, L. Leibovici, Y. Carmeli O0520Genomic analysis of Salmonella entericaserovar Kentucky ST198 strains isolated over 10 years from clinical cases in Switzerland M. Biggel* (Zurich, Switzerland), J. Horlborg, M. Nüesch-Inderbinen, R. Stephan OS123 16:15 - 18:15 Hall K 2-Hour Oral Session What’s fast, new and relevant in infectious disease diagnostics? ChairsTruls Michael Leegaard (Lørenskog, Norway) Carmen Munoz-Almagro (Barcelona, Spain) O0521Improvement of pre-analytical workflow in a clinical laboratory using lean principles combined with lab automation: impact of the WASP® integration in Hospital General Universitario de Albacete, Spain V. González* (Madrid, Spain), E. Escribano, J. Lozano, J. Parra, A. Garcia, P. Martin, N. Salas, S. Sierra, C. Sainz De Baranda O0522Comparison of conventional culture with T2MR technology for microbial pathogen detection in non-blood specimens collected from paediatric patients M. Agosta* (Rome, Italy), L. Mancinelli, B. Lucignano, M. Onori, S. Al Bitar Nehme, G. Mattana, M. Argentieri, L. Pansani, A. Sisto, A. Santisi, F. Tortora, T. Fragasso, C.F. Perno, P. Bernaschi O0523Comparison of the APAS Independence Automated Plate Reader System with manual Standard-of-Care for processing urine culture specimens D. Pride* (La Jolla, United States), P. Kuo, M. Chiu, P. Ramos, R. Barba O0524Fast lipid analysis technique (FLAT) a rapid, direct from urine diagnostic assay for identification of Gram-negative pathogens R. Ernst* (Baltimore, United States), H. Yang, R. Smith, A. Joshi, D. Goodlett, J. Jennifer O0525Evaluation of a prototype molecular assay to differentiate bacterial versus viral infections from whole blood based on host gene expression M. Faron* (Milwaukee, United States), B. Mesich, A. Cruz, E. Wallace, F. Strouts, D. Persing O0526In vitro pathogen differentiation by mass spectrometry based detection of C-terminal alpha-1-antitrypsin peptides F. Scherr* (Jena, Germany), L. Kasper, F.DEP Hoffmann, S. Neugebauer, B. Hube, L. Tuchscherr, F. Von Eggeling, M. Kiehntopf O0527Electrochemical monitoring of metabolites for detection and label-free identification of microorganisms: towards a smart blood-culture bottle T. Cohu* (Saint-Martin-D’hères, France), P.R. Marcoux, M. Gougis, P. Mailley O0528Clinical evaluation of a new selective medium for non-tuberculous mycobacteria: a prospective multi-centre study J. Esteban* (Madrid, Spain), A. Broncano-Lavado, L. Barrado-Blanco, J. Cacho-Calvo, D. Domingo, J. Garcia-Martinez, S. Hernandez, P. Lopez-Roa, R. Millan-Perez, E. Perez-Cecilia, M.J. Ruiz-Serrano, S. Salso-Ortiz, M. Simon-Sacristan, M. Tato-Diez, C. Toro-Rueda, J.F. Valverde-Canovas O0529Application of MALDI-TOF MS and machine learning for differentiation between the subspecies from Mycobacterium abscessus complex D. Rodriguez-Temporal* (Madrid, Spain), L. Herrera, M.J. Ruiz-Serrano, P. Muñoz, B. Rodríguez-Sánchez O0530Impact of routine molecular point-of-care testing for respiratory pathogens in critically unwell patients with pneumonia: a pragmatic, open- label, randomised controlled trial S. Poole* (Southampton, United Kingdom), A.R. Tanner, V.V. Naidu, F. Borca, H.T.T. Phan, K. Saeed, M.P.W. Grocott, A. Dushianthan, N.J. Brendish, H.E. Moyses, T.W. Clark VW124 16:15 - 17:15 Arena 2 Virtual Walk Through Standardised methods for antimicrobial susceptibility testing ModeratorHelena Zemlickova (Prague, Czech Republic) ReviewerLaurent Dortet (Le Kremlin-Bicêtre, France)78FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Overview Monday, 25 April 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall AHall BHall CHall DHall EHall F 07:15 - 08:15 ME125 ESCMID & IDSA treatment guidelines for MDR Gram- negative bacterial infections 08:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:30 SY132SY133OS138SY134EW137 Long-read sequencing:from benchtop to bedside Severe skin and soft tissue infection Attractive tools aiding the diagnosis of fungal infections Past, present and future of pandemics: preparedness and firstdefense Infectiousbiofilm in the healthcare environment 11:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:00 KN143SY144SY145OS156SY146OS153 Beyond species ID: Innovative uses of MALDI-TOF in the clin- ical microbiology lab Tuberculous menin- gitis Management of difficult-to-treat antibiotic-resistant cases Novel observations in protective host re- sponses to infection Advances in clinical antibacterial resistance research Communicating COVID-19: fact and fiction 13:30 - 15:3013:30 - 15:3013:30 - 14:3013:30 - 14:3013:30 - 15:30 SY161EW164OS168SY162EW165 Antifungal prophylax- is in transplantation: abenefitforwhich patients? Complicated endovascular infections Changing world of infectious diseases: urbanisation and digitalisation The role of genomics in AMR surveillance Year in Infection Control 14:45 - 15:4514:45 - 15:4514:45 - 15:45 KN171OS175SY172 Invasive fungal infections in the immunocompromised Harnessing deep learning and synthetic biology to fightpathogens AI in infectious disease management and control 16:15 - 18:1516:15 - 18:1516:15 - 17:1516:15 - 18:1516:15 - 18:15 SY178EW182OS185SY179SY180 Fungal diagnosis: questionsfromthe bedside and answers from the bench Uncommon systemic infections Gut reaction: the connection between biofilmsanddisease Sepsis 2022: prevent it, spot it, treat it, beat it Late-breaking research from Clinical Microbiology and Infection journal ID ID ID ID IDID CM CMCM CM CM IC IC IC PH PH PH PHScientific Programme 79FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall GHall HHall IHall JHall KHall L 07:15 - 08:1507:15 - 08:1507:15 - 08:1507:15 - 08:15 ME126ME127ME128ME129 Reconciling sepsis initiatives and antimicrobial stewardship programmes Hepatitis D Virus: the neglected viral hepatitis How I treat infections in patients awaiting solid organ transplantation Driving the response to EIDs in LMICs with genomics and bioinformatics 08:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:3008:30 - 10:30 SY135OS139OS140SY136OS141 HIV and the reservoir: what is new? Epidemic dynamics and transmission during the COVID-19 pandemic Clinical consider- ations for tropical disease management ESCMID Guidelines for the treatment of infections caused by multidrug-resistant Gram-negatives: a case-based approach Cutting edge in mycobacterial research 11:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:0011:00 - 12:00 OS154SY147SY152SY148OF157OF158 Novel combinations with potential to treat highly resistant pathogens Using water to monitor circulating pathogens Antimicrobial resistance and COVID-19: increase or decrease? Prediction and prognosis of Staphylococcus aureus pneumonia Diagnostics in clinicalandscientific parasitology Virus surveillance across different settings 12:15 - 13:15 IS38 Rapid culture- independent diagnostics charting a new course for sepsis management and antimicrobial stewardship 13:30 - 15:3013:30 - 14:3013:30 - 14:3013:30 - 14:3013:30 - 14:3013:30 - 15:30 EW166OF169SY163OS167OF170IS42 Recent top papers in transplant ID and haem/onc ID Real-life COVID-19 vaccine effectiveness Influenzavacci- nation: protection beyondflu Antimicrobial tolerance in pathogens: bench to bedside Community-acquired central nervous system infections Potential diagnostic tools for monitoring hepatotropic infections 14:45 - 15:4514:45 - 15:4514:45 - 15:45 SY173OS174OF176 Does AMR mitigation inLMICsrequiretech- nical capacity more than funding? Secondary infections in COVID-19 Antibiotic stewardship in hospitals and primary care 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:15 SY181OS184EW183IS47 Microbial diversity studies across diverse settings Prevention of nosocomial bloodstream infections What matters in the fightagainstCOVID-19: how to keep high levels of protection in a multi- variant environment? Unveiling the mysteries of FMT efficacy ID ID ID ID ID ID ID CM CMCM CM CM IC PH Colour Key Educational Workshops, Meet-the-Expert Sessions Sessions specifically interesting for: Infectious Disease specialists Symposia (1h/2h)Oral sessions (1h/2h) Keynote Lectures Clinical Microbiologists Infection Control specialistsPublic Health specialists CM IDIC Open Forum & Virtual Walk Throughs PH Integrated Symposia & Pipeline Corners are not detailed in this book. Please refer to the Industry Guide for session details.Next >